Open in interactive viewer → charts, metric popovers & call review

Paysign’s Patient-Affordability Engine Is Now the Whole Story — and It’s Hiding a Plasma Hole

Record Q3 margins and 110% pharma growth let management raise profitability guidance while a 113-center plasma defection looms and Apherion’s FDA timeline slips again.
PAYS · Earnings Call · 2026-11-09

The income statement finally looks like a software company

Paysign’s Q3 2026 print is not a subtle improvement. Revenue rose 43% to $30.8 million, net income more than tripled to $6.7 million, operating margin went from 7.3% to 23.8%, and adjusted EBITDA doubled to $11 million. The cause is visible in the mix: patient affordability revenue more than doubled to $16.6 million and is now bigger than plasma, while gross margin expanded 840 basis points to 64.7%. “We expect gross and operating margins to continue to expand as patient affordability becomes a greater part of our revenue mix.” — Mark Newcomer, President and Chief Executive Officer · 2026-11-09 That is the whole bull case in one sentence. The equity has already noticed: the stock is up 86.8% over the last 90 trading days, and the company now carries a $572 million market cap. But the same report contains a 113-center plasma customer loss and a regulatory review that has slipped again. So the real question is not whether Q3 was strong. It is whether the market is now paying for the new mix while underestimating the hole in the old one.

Patient affordability is doing the work — and hiding the seasonality

The patient affordability engine grew revenue 109.8% and claim volume rose about 55%. Paysign launched 19 new programs in the quarter, exited with 167 active programs, and expects to end the year at 190 to 195, adding 59 to 64 programs versus 55 last year. Average quarterly revenue per program rose 32% to $99,524. That last number matters: it says the growth is not just more logos; existing programs are deepening. Management also points to dynamic business rules as the measurable value driver — the platform insulated clients from $82.5 million of co-pay maximizer and accumulator costs in Q3 alone, $553 million year-to-date, and $923 million cumulatively. Those are the kind of numbers that make a pharma buyer reluctant to switch. The interesting admission is on seasonality. “As we keep onboarding more and more programs, it does hide the seasonality.” — Matthew Turner, President of Pharmaceutical Business · 2026-11-09 In plain English, Q3’s strength is not a normal seasonal pattern; it is program onboarding plus utilization. That is a better story than a seasonal bounce, but it also means the market should not extrapolate the sequential slope. The company’s own guidance — $114 million to $117 million of full-year revenue — implies Q4 remains strong but not a repeat of the Q3 step-up.

The plasma customer loss is not a rounding error

The plasma business still grew 7.5% to $13.8 million, and average monthly revenue per center rose 14.9% to $8,187 on stronger center utilization. But one plasma customer is moving 113 centers to another provider by year-end, consolidating with a banking partner. Management says the decision was not service-related and that it remains the processor for other centers at that customer. The financial hole is real: “These centers represented approximately $11.3 million in revenue and $5.15 million in gross profit over the previous 12 months ending September 2026.” — Jeffery Baker, Chief Financial Officer · 2026-11-09 For Q4 alone, the company expects a $1.5 million revenue hit and $700,000 of gross profit lost. The center count tells the scale: Paysign served 562 centers in Q3 and expects to exit the year at 445 to 450. That is roughly a fifth of the base. Management argues it can replace the lost centers over the next couple of quarters and says it is in active discussions with prospective plasma clients. Maybe. But plasma is the cash cow that funds the story, and the loss is bigger than the routine center closures of prior quarters. The bull case can absorb it because patient affordability is growing fast enough to raise full-year profitability guidance anyway. The bear case says plasma is now a shrinking base, not a dependable annuity.

Apherion has become the keyword that will not ship

The Apherion software platform is the company’s freshest strategic theme — the plasma software suite meant to extend Paysign from payments into donor management and European operations through its Dublin subsidiary. It is also the clearest example of a timeline that keeps moving. On the Q3 call, management was asked for an FDA update and said:

We don't have a time line at this point. We're waiting to hear back from the regulators on that. And as soon as we do, we'll give you guys an update.

Matthew Turner, President of Pharmaceutical Business · 2026-11-09
That is a long way from the prior calls. In August 2025: “We're targeting currently towards the end of this year. We're expecting that we will be granted approval around that time frame.” — Mark R. Newcomer, President and Chief Executive Officer · 2025-08-05 By March 2026: “We expect to hear back from them within the next 60 days.” — Mark Newcomer, President and Chief Executive Officer · 2026-03-24 Now there is no date, and when asked whether this was the second or third round of questions, the CEO said, “I really can't speak to that at this point.” — Mark Newcomer, President and Chief Executive Officer · 2026-11-09 Regulatory Q&A can be unpredictable, but investors should treat Apherion as optionality, not a near-term catalyst, until a date is actually set.

What the tape and balance sheet are saying

This is not a sleepy microcap any more. The 90-day move is +86.8%, and the stock sits about 14.8% below its 2019 high. At $572 million of market cap, the market is no longer valuing Paysign on plasma alone; it is capitalizing the patient affordability margin stream. The last filed quarter showed $171 million of effective net cash, but the Q3 call clarifies that only $34.5 million was unrestricted cash, with $201.8 million of restricted cash tied to customer program deposits and funds on card. The balance sheet is clean — zero bank debt — but the cash is not all deployable. The stock has already re-rated. The next leg needs either Apherion approval or evidence that patient affordability program adds are not just a 2026 onboarding wave. Q4 should answer the first-order questions: does the 113-center transition close without further customer losses, does the full-year revenue guide hold at $114 million to $117 million, and does the financial assistance platform keep converting new programs into the same revenue-per-program lift? Q3 was a genuine operating inflection. It was not a clean quarter.